Navigation Links
EVMS receives more than $1 million in federal funds to develop new ways to reverse type 1 diabetes

Researchers at the Eastern Virginia Medical School Strelitz Diabetes Center have been awarded a $1,076,250 grant by the Department of Defense (DoD) Peer Reviewed Medical Research Program to develop new ways of reversing the underlying causes of Type 1 diabetes.

David Taylor-Fishwick, PhD, associate professor of internal medicine and director of the Cell, Molecular and Islet Biology Laboratory, leads the team whose research applies to both regenerative and autoimmune medicine.

"Type 1 diabetes is caused by an autoimmune attack that destroys the insulin-producing beta cells, and the body does not automatically regenerate or replace these cells," explains Dr. Taylor-Fishwick. "The unique challenge in reversing Type 1 diabetes is to regenerate the insulin-producing beta cells and to stop the body's autoimmune attack."

Insulin is the hormone that helps the body convert glucose from food into energy. When the beta cells are destroyed, no insulin can be produced. Insulin replacement therapy helps the body maintain normal glucose levels, but doesn't prevent the serious diabetes health problems such as blindness, nerve damage, heart disease and kidney failure.

Dr. Taylor-Fishwick's research on beta cell regeneration has focused on INGAP (Islet Neogenesis Associated Protein), branded as Exsulin, the breakthrough discovery made by Aaron I. Vinik, PhD, MD, director of research at the Strelitz Diabetes Center, and Dr. Lawrence Rosenberg of McGill University. Published trials of Exsulin demonstrated promising results in both Type 1 and Type 2 diabetes patients.

The DoD grant will fund the next phase in the team's research finding a way to neutralize the immune system's attack of the beta cells. This immune attack occurs at the onset of diabetes and may continue after Type 1 diabetes has appeared. The benefits of this research may also apply to other autoimmune diseases such as lupus and rheumatoid arthritis.

Dr. Taylor-Fishwick and his team will test several experimental drugs developed by Jerry Nadler, MD, chair of internal medicine and director of the EVMS Strelitz Diabetes Center. The compounds are designed to modify the autoimmune response and stabilize beta cells. The goal is to develop these compounds into an oral pill.

"The Department of Defense, through its Congressionally Directed Medical Research Program, is especially interested in research to combat autoimmunity," Dr. Taylor-Fishwick says. "So part of our work is to block the process of autoimmunity that occurs in diabetes. We are using a drug called Lisofylline (LSF) and related molecules to block interleukin-12, a protein that triggers the autoimmune response," he explains. "By targeting interleukin-12 signaling, we hope to redirect the immune system, but not wipe it out."

The researchers hope that one of these compounds, when used in conjunction with Exsulin, may help to create a combination therapy regimen that could achieve a functional cure for Type 1 diabetes.


Contact: Jina Gaines
Eastern Virginia Medical School

Related medicine news :

1. US Wellness, Inc. Receives National Recognition for Laboratory Excellence
2. American Public Health Champion Receives 2010 Stockholm Water Prize
3. Society for New Communications Research Receives Grant to Help Raise Awareness and Reduce Racial and Ethnic Health Disparities
4. BUSM researcher receives prestigious young investigator award
5. Yondelis(R) Receives Five New Approvals Outside the European Economic Area
6. Christiana Care Health Systems Darcy Burbage Receives Oncology Nursing Society Award
7. Moleac Receives BioSpectrum Asia Emerging Company of the Year 2010 Award
8. CoreObjects Receives Project Management Institutes Excellence Award for Diabetes Contribution
9. Zimmer Receives Recognition for Health Economics Data Presented at 77th Annual American Academy of Orthopaedic Surgeons Meeting
10. U.S. Senator Kit Bond Receives 2010 AOA Health Care Leadership Award
11. Intellimed's Popular Data Reporting Software IM-IC (Intelligent Client) Receives Latest Update
Post Your Comments:
Related Image:
EVMS receives more than $1 million in federal funds to develop new ways to reverse type 1 diabetes
(Date:11/27/2015)... ... 2015 , ... Dr. Thomas Dunlap and Dr. Patrick Coleman ... with Emergency Medicine at St., Joseph Health System’s Santa Rosa Memorial Hospital , ... in similar ways and require time-critical intervention to avoid large area heart damage and ...
(Date:11/27/2015)... ... 27, 2015 , ... Indosoft Inc., developer and distributor of ... 11 LTS (Long Term Support) into its Q-Suite 5.10 product line. , Making ... with a version of Asterisk that will receive not only security fixes, but ...
(Date:11/26/2015)... ... November 26, 2015 , ... Inevitably when people think Thanksgiving, they ... to buy during the Black Friday and Cyber Monday massage chair sales ... the Internet high and low to find the best massage chair deals, they can ...
(Date:11/26/2015)... ... November 26, 2015 , ... Somu Sivaramakrishnan announced today that ... Somu now offers travelers, value and care based Travel Services, including exclusive pricing ... well as, cabin upgrades and special amenities such as, shore excursions, discounted fares, ...
(Date:11/26/2015)... Omaha, NE (PRWEB) , ... November 26, 2015 , ... ... careers searched by healthcare professionals and offered by healthcare staffing agency Aureus Medical ... top during the month of October 2015 among those searching for healthcare jobs through ...
Breaking Medicine News(10 mins):
(Date:11/25/2015)... 26, 2015  The total global healthcare industry is expected ... Latin America has the highest projected ... Japan ), is second with growth projected ... face increased healthcare expenditure. In 2013-2014, total government funded healthcare ... in 2008-2009 to 41.2% in 2013-2014. In real terms, out ...
(Date:11/25/2015)... , Nov. 25, 2015 AAIPharma ... planned investment of at least $15.8  Million to ... Wilmington, NC . The expansion will ... to meet the growing demands of the pharmaceutical ... site expansion will provide up to 40,000 ...
(Date:11/25/2015)... AVIV, Israel , November 25, 2015 ... (NASDAQ: KTOV ) (TASE: KTOV), a biopharmaceutical company ... simultaneous treatment of various clinical conditions, today announced the ... 3,158,900 American Depository Shares ( ADSs ), each representing ... purchase up to 3,158,900 ADSs. The ADSs and warrants ...
Breaking Medicine Technology: